Mumbai-based Lupin Pharmaceuticals is expecting approval from US health regulators to launch about 30 generic drugs into the US market, the world’s largest for pharmaceuticals. At the moment the company has 162 abbreviated new drug applications (ANDAs) which are waiting for approval from the USFDA, (United States Food and Drug Administration.)

The company has its sights set on bringing complex generic drugs and biosimilars to the US market, in addition to continuing to focus on several exclusive and semi-exclusive products in the injectable and oral niche to keep its place as the fourth largest generics company in the market by prescriptions sold.

“We launched 23 products in the US last fiscal (2017-18), with 10 in the last quarter (January-March) alone. We expect to launch 25-30 products in US this year,” Lupin Managing Director Nilesh Gupta.

“Our efforts to maintain leadership position include bringing complex generics and biosimilars to market while continuing our focus on exclusive and semi-exclusive products in the oral and injectable space,” Gupta said.

During the fiscal year 2018 the company is hoping to launch about 30 specific products in to the US market.